Results 291 to 300 of about 745,482 (386)

Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer

open access: yesClinical Infectious Diseases, 2018
Tilly A. Varughese   +11 more
semanticscholar   +1 more source

Single‐Cell Mitochondrial Lineage Tracing Decodes Fate Decision and Spatial Clonal Architecture in Human Hematopoietic Organoids

open access: yesAdvanced Science, EarlyView.
This study repurposes mitochondrial DNA mutations as endogenous barcodes for lineage tracing in human pluripotent stem cell‐derived organoids. Integrated with transcriptomic and spatial data, it reveals NOTCH‐mediated stromal‐progenitor crosstalk orchestrates clonal dynamics and spatial zonation during early hematopoietic development, offering a non ...
Yan Xue   +17 more
wiley   +1 more source

Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD

open access: yesHaematologica, 2018
Diego Villa   +14 more
doaj   +1 more source

Accumulation of Lymphoid Progenitors with Defective B Cell Differentiation and of Putative Natural Killer Progenitors in Aging Human Bone Marrow. [PDF]

open access: yesInt J Mol Sci
Poisa-Beiro L   +10 more
europepmc   +1 more source

Engineered Small Extracellular Vesicles Targeting Tumor‐Associated Endothelial Cells to Effectively Remodel the Glioma Microenvironment

open access: yesAdvanced Science, EarlyView.
This study developed a novel drug delivery platform that overcomes the blood‐brain barrier in glioblastoma. By fusing IGFBP7 with small extracellular vesicles, the platform specifically targets tumor vasculature. It effectively delivers temozolomide, suppressing tumor growth at low doses.
Lingling Liu   +17 more
wiley   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

open access: yesAdvanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang   +7 more
wiley   +1 more source

CD19‐CAR T‐cell therapy with sorafenib in post‐HSCT relapse of mixed phenotype acute leukaemia (MPAL) with phenotypic myeloid to lymphoid lineage switch—A case report and review of the literature

open access: green
Aleksandra Oszer   +17 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy